334 related articles for article (PubMed ID: 33351306)
1. [Darolutamide: A new drug for non-metastatic castration-resistant prostate cancer].
Zhang F; Lu YP
Zhonghua Nan Ke Xue; 2020 Apr; 26(4):364-368. PubMed ID: 33351306
[TBL] [Abstract][Full Text] [Related]
2. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
Fizazi K; Smith MR; Tombal B
Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
[TBL] [Abstract][Full Text] [Related]
3. Darolutamide (ODM-201) for the treatment of prostate cancer.
Shore ND
Expert Opin Pharmacother; 2017 Jun; 18(9):945-952. PubMed ID: 28490267
[TBL] [Abstract][Full Text] [Related]
4. Darolutamide for treatment of castration-resistant prostate cancer.
Rhea LP; Mendez-Marti S; Aragon-Ching JB
Drugs Today (Barc); 2020 Mar; 56(3):185-193. PubMed ID: 32282865
[TBL] [Abstract][Full Text] [Related]
5. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.
Esther J; Maughan BL; Anderson N; Agarwal N; Hahn AW
Curr Treat Options Oncol; 2019 Feb; 20(2):14. PubMed ID: 30741354
[TBL] [Abstract][Full Text] [Related]
6. Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison.
Chowdhury S; Oudard S; Uemura H; Joniau S; Dearden L; Capone C; Van Sanden S; Diels J; Hadaschik BA
Adv Ther; 2022 Jan; 39(1):518-531. PubMed ID: 34797506
[TBL] [Abstract][Full Text] [Related]
7. Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.
Ming J; Wu Y; Han R; Xu X; Waldeck R; Hu S
Adv Ther; 2023 Mar; 40(3):1087-1103. PubMed ID: 36630046
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of darolutamide in Black/African-American patients from the phase III ARAMIS study.
Shore ND; Cruz F; Nordquist L; Belkoff L; Aronson WJ; Tolia B; Cinman A; Sharifi R; Ortiz J; Parkin J; Srinivasan S; Sarapohja T; Smith MR
Future Oncol; 2022 Dec; 18(40):4473-4482. PubMed ID: 36753353
[TBL] [Abstract][Full Text] [Related]
9. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial.
Smith MR; Shore N; Tammela TL; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Kuss I; Le Berre MA; Mohamed AF; Odom D; Bartsch J; Snapir A; Sarapohja T; Fizazi K
Eur J Cancer; 2021 Sep; 154():138-146. PubMed ID: 34273811
[TBL] [Abstract][Full Text] [Related]
10. Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer.
Appukkuttan S; Farej R; Miles L; Purser M; Wen L
J Manag Care Spec Pharm; 2021 Feb; 27(2):166-174. PubMed ID: 33141615
[No Abstract] [Full Text] [Related]
11. Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.
Scott LJ
Target Oncol; 2020 Dec; 15(6):791-799. PubMed ID: 33237495
[TBL] [Abstract][Full Text] [Related]
12. Treatment and trials in non-metastatic castration-resistant prostate cancer.
Lokeshwar SD; Klaassen Z; Saad F
Nat Rev Urol; 2021 Jul; 18(7):433-442. PubMed ID: 34002069
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial.
Uemura H; Matsushima H; Kobayashi K; Mizusawa H; Nishimatsu H; Fizazi K; Smith M; Shore N; Tammela T; Tabata KI; Matsubara N; Iinuma M; Uemura H; Oya M; Momma T; Kawakita M; Fukasawa S; Kobayashi T; Kuss I; Le Berre MA; Snapir A; Sarapohja T; Suzuki K
Int J Clin Oncol; 2021 Mar; 26(3):578-590. PubMed ID: 33226524
[TBL] [Abstract][Full Text] [Related]
14. An up-to-date evaluation of darolutamide for the treatment of prostate cancer.
Moussa M; Lazarou L; Dellis A; Abou Chakra M; Papatsoris A
Expert Opin Pharmacother; 2021 Mar; 22(4):397-402. PubMed ID: 33135506
[No Abstract] [Full Text] [Related]
15. Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis.
Carles J; Medina-Lopez RA; Puente J; Gómez-Ferrer Á; Nebra JC; Sáez Medina MI; Ribal MJ; Antolín AR; Álvarez-Ossorio JL; Suárez Novo JF; Agut CM; Srinivasan S; Ortiz J; Fizazi K
Future Oncol; 2023 Apr; 19(12):819-828. PubMed ID: 37222151
[TBL] [Abstract][Full Text] [Related]
16. Using darolutamide in advanced prostate cancer: How I Do It.
Hamilton J
Can J Urol; 2021 Jun; 28(3):10673-10677. PubMed ID: 34129460
[TBL] [Abstract][Full Text] [Related]
17. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
Mori K; Mostafaei H; Pradere B; Motlagh RS; Quhal F; Laukhtina E; Schuettfort VM; Abufaraj M; Karakiewicz PI; Kimura T; Egawa S; Shariat SF
Int J Clin Oncol; 2020 Nov; 25(11):1892-1900. PubMed ID: 32924096
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial.
Shore N; Zurth C; Fricke R; Gieschen H; Graudenz K; Koskinen M; Ploeger B; Moss J; Prien O; Borghesi G; Petrenciuc O; Tammela TL; Kuss I; Verholen F; Smith MR; Fizazi K
Target Oncol; 2019 Oct; 14(5):527-539. PubMed ID: 31571095
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis.
Zhang X; Zhang G; Wang J; Bi J
Front Endocrinol (Lausanne); 2023; 14():1131033. PubMed ID: 36843606
[TBL] [Abstract][Full Text] [Related]
20. Decisions and dilemmas in non-metastatic castration-resistant prostate cancer management.
Tartarone A; Lerose R; Tartarone M
Med Oncol; 2022 May; 39(7):107. PubMed ID: 35553247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
